Print Page  Close Window

Investor Relations

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).

NASDAQ | AVEO (Common Stock)
$0.75 - 0.04
Stock chart for: AVEO.O.  Currently trading at $0.75 with a 52 week high of $1.15 and a 52 week low of $0.50.
05/26/17 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell CarcinomaRead More
AVEO Announces Appointment of Matthew Dallas as Chief Financial OfficerRead More
AVEO Issues Statement Regarding the Passing of Lead Director Henri A. TermeerRead More